Enliven Therapeutics (ELVN) Stock Chart & Stock Price History $16.86 -0.52 (-2.98%) As of 03:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Enliven Therapeutics Stock Price Performance The Enliven Therapeutics (ELVN) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 26.37%, with a year-to-date return of -25.06%. In the past month, the stock has increased 3.96%, reflecting recent market activity. As of the latest close, Enliven Therapeutics traded at $17.38 with a market cap of $852.82 million and volume of 333,003 shares. Receive ELVN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+0.01%1 Month Performance+3.96%3 Month Performance-22.65%Year-To-Date Performance-25.06%1 Year Performance-26.37% ELVN Stock Chart for Wednesday, May, 21, 2025 ELVN Chart by TradingView Enliven Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/20/2025$16.85$17.38+3.15%$17.54$16.57333,003 shs$852.82 million05/19/2025$16.86$16.85-0.06%$17.28$15.91349,850 shs$826.81 million05/16/2025$17.82$16.86-5.39%$18.54$16.65473,950 shs$827.25 million05/15/2025$19.89$17.82-10.41%$20.00$16.27800,108 shs$874.36 million05/14/2025$20.03$19.89-0.70%$20.96$19.53400,370 shs$975.92 million05/13/2025$19.01$20.03+5.37%$20.46$18.82345,696 shs$982.79 million05/12/2025$18.51$19.01+2.70%$19.85$18.62473,427 shs$932.75 million05/09/2025$18.63$18.51-0.64%$19.67$18.25511,962 shs$908.21 million05/08/2025$18.28$18.63+1.90%$19.42$17.99412,961 shs$914.10 million05/07/2025$19.69$18.28-7.15%$19.80$17.76254,358 shs$897.07 million Get the Latest News and Ratings for ELVN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/06/2025$20.39$19.69-3.43%$20.35$18.96594,529 shs$966.11 million05/05/2025$20.51$20.39-0.59%$20.60$19.96238,032 shs$1.00 billion05/02/2025$19.85$20.51+3.32%$20.79$19.65221,177 shs$1.01 billion05/01/2025$18.94$19.85+4.80%$20.16$18.57216,036 shs$972.73 million04/30/2025$18.65$18.94+1.55%$19.22$17.82157,800 shs$928.14 million04/29/2025$18.91$18.65-1.37%$19.08$18.19216,047 shs$913.93 million04/28/2025$18.21$18.91+3.84%$19.19$17.81318,922 shs$926.67 million04/25/2025$18.30$18.21-0.49%$18.40$17.46124,974 shs$892.36 million04/24/2025$17.77$18.30+2.98%$18.57$17.36249,987 shs$896.77 million04/23/2025$17.97$17.77-1.11%$19.61$17.71180,903 shs$870.80 million04/22/2025$16.22$17.97+10.79%$18.23$16.45508,007 shs$880.60 million04/21/2025$16.53$16.22-1.88%$16.82$15.44282,227 shs$794.85 million Related Companies Arcellx Stock Chart Metsera Stock Chart Viking Therapeutics Stock Chart Akero Therapeutics Stock Chart Alvotech Stock Chart Catalyst Pharmaceuticals Stock Chart Crinetics Pharmaceuticals Stock Chart Scholar Rock Stock Chart Merus Stock Chart MorphoSys Stock Chart Receive ELVN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ELVN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.